Trading Report: Today, Regulus Therapeutics Inc. (RGLS) Receives Consensus Recommendation of “Buy” from Analysts

Today, Regulus Therapeutics Inc. (RGLS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the stock. Three analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $9.80.

Several brokerages have recently issued reports on RGLS. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Thursday, August 4th. Cowen and Company cut Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 2nd. Wedbush reissued an “outperform” rating and issued a $15.00 price objective (up previously from $13.00) on shares of Regulus Therapeutics in a report on Wednesday, November 2nd. Finally, Wells Fargo & Co. reissued an “outperform” rating on shares of Regulus Therapeutics in a report on Sunday, July 31st.

Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down 3.70% on Monday, hitting $2.60. The stock had a trading volume of 259,590 shares. Regulus Therapeutics has a 12 month low of $2.12 and a 12 month high of $10.60. The company’s 50 day moving average price is $2.80 and its 200-day moving average price is $3.78. The company’s market cap is $137.60 million.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in Regulus Therapeutics by 8.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 114,400 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 8,800 shares during the period. Highbridge Capital Management LLC bought a new position in Regulus Therapeutics during the third quarter worth about $343,000. D. E. Shaw & Co. Inc. bought a new position in Regulus Therapeutics during the third quarter worth about $187,000. Piermont Capital Management Inc. raised its position in Regulus Therapeutics by 9.3% in the third quarter. Piermont Capital Management Inc. now owns 166,104 shares of the biopharmaceutical company’s stock worth $548,000 after buying an additional 14,180 shares during the period. Finally, Morgan Stanley raised its position in Regulus Therapeutics by 13.2% in the third quarter. Morgan Stanley now owns 31,708 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 3,699 shares during the period. Hedge funds and other institutional investors own 49.95% of the company’s stock.

Related posts

Leave a Comment